NASDAQ:ORIC Oric Pharmaceuticals (ORIC) Stock Price, News & Analysis $8.82 +0.33 (+3.89%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$8.82 0.00 (0.00%) As of 11/6/2026 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Oric Pharmaceuticals Stock (NASDAQ:ORIC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oric Pharmaceuticals alerts:Sign Up Key Stats Today's Range$8.50▼$8.9350-Day Range$8.49▼$13.8552-Week Range$7.23▼$14.68Volume556,748 shsAverage Volume2.07 million shsMarket Capitalization$914.19 millionP/E RatioN/ADividend YieldN/APrice Target$21.25Consensus RatingModerate Buy Company Overview Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) is a clinical-stage biopharmaceutical company focused on developing medicines that overcome mechanisms of treatment resistance in cancer. The company uses its discovery platform to identify therapies intended to improve or restore the effectiveness of existing cancer treatments. Oric’s pipeline has included ORIC-533, an oral small-molecule inhibitor of CD73 designed to block adenosine-mediated immunosuppression in the tumor microenvironment. The company has evaluated the program in hematologic malignancies, including multiple myeloma. Its research and development activities have also included therapies directed at epigenetic and growth-signaling pathways implicated in solid tumors, such as PRC2 and EGFR/HER2. Founded in 2014 and headquartered in South San Francisco, California, Oric conducts its research and clinical-development activities primarily in the United States, with programs intended for potential use in cancer patients internationally. The company is led by President and Chief Executive Officer Jacob Chacko, M.D.AI Generated. May Contain Errors. Read More Oric Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreORIC MarketRank™: 2.19804134929 of 5 starsOric Pharmaceuticals scored higher than 44% of companies evaluated by MarketBeat, and ranked 464th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingOric Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on no strong buy ratings, 14 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialOric Pharmaceuticals has a consensus price target of $21.25, representing about 140.9% upside from its current price of $8.82.Amount of Analyst CoverageOric Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Oric Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Oric Pharmaceuticals are expected to decrease in the coming year, from ($1.53) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oric Pharmaceuticals is -6.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oric Pharmaceuticals is -6.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOric Pharmaceuticals has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Oric Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.78% of the float of Oric Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOric Pharmaceuticals has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Oric Pharmaceuticals has recently decreased by 5.48%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOric Pharmaceuticals does not currently pay a dividend.Dividend GrowthOric Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 4 news articles for Oric Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for ORIC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Oric Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,432,952.00 in company stock.Percentage Held by Insiders5.70% of the stock of Oric Pharmaceuticals is held by insiders.Percentage Held by Institutions95.05% of the stock of Oric Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Oric Pharmaceuticals' insider trading history. Receive ORIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oric Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORIC Stock News HeadlinesORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)November 6 at 4:30 PM | globenewswire.comOric Pharmaceuticals (ORIC) Projected to Release Earnings on ThursdayNovember 5 at 3:41 AM | americanbankingnews.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found. | Crypto 101 Media (Ad)ORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 3, 2026 | globenewswire.comOric Pharmaceuticals (NASDAQ:ORIC) Earns Buy Rating from BTIG ResearchOctober 30, 2026 | americanbankingnews.comWedbush Issues Pessimistic Forecast for Oric Pharmaceuticals (NASDAQ:ORIC) Stock PriceOctober 29, 2026 | americanbankingnews.comWedbush Adjusts Price Target on ORIC Pharmaceuticals to $14 From $17, Keeps Outperform RatingOctober 27, 2026 | marketscreener.comMOric Pharmaceuticals (NASDAQ:ORIC) Stock: Insider Dominic Piscitelli Sells 14,000 SharesOctober 22, 2026 | insidertrades.comSee More Headlines ORIC Stock Analysis - Frequently Asked Questions How have ORIC shares performed this year? Oric Pharmaceuticals' stock was trading at $8.18 at the beginning of 2026. Since then, ORIC shares have increased by 7.8% and is now trading at $8.82. How were Oric Pharmaceuticals' earnings last quarter? Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) posted its quarterly earnings data on Monday, May, 4th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.03. When did Oric Pharmaceuticals IPO? Oric Pharmaceuticals (ORIC) raised $112 million in an initial public offering on Friday, April 24th 2020. The company issued 7,500,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities acted as the underwriters for the IPO. Who are Oric Pharmaceuticals' major shareholders? Top institutional investors of Oric Pharmaceuticals include Candriam S.C.A. (0.76%), Russell Investments Group Ltd. (0.15%), Profund Advisors LLC (0.04%) and China Universal Asset Management Co. Ltd.. Insiders that own company stock include Jacob Chacko, Dominic Piscitelli, Pratik S Multani and Angie You. View institutional ownership trends. How do I buy shares of Oric Pharmaceuticals? Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oric Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oric Pharmaceuticals investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Viking Therapeutics (VKTX), Amprius Technologies (AMPX), IonQ (IONQ), SoFi Technologies (SOFI) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/03/2026Today11/08/20263rd Annual Guggenheim Healthcare Innovation Conference11/10/2026Stifel 2026 Healthcare Conference 202611/11/2026Next Earnings (Estimated)11/12/2026Jefferies Global Healthcare Conference11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 4 days ago, ORIC's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ORIC CIK1796280 Webwww.oricpharma.com Phone650-388-5600FaxN/AEmployees111Year Founded2014Price Target and Rating Average Price Target for Oric Pharmaceuticals$21.25 High Price Target$27.00 Low Price Target$14.00 Potential Upside/Downside+140.9%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$129.47 million Net MarginsN/A Pretax MarginN/A Return on Equity-35.35% Return on Assets-33.39% Debt Debt-to-Equity RatioN/A Current Ratio13.19 Quick Ratio13.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.90 per share Price / Book2.26Miscellaneous Outstanding Shares103,650,000Free Float97,745,000Market Cap$914.19 million OptionableOptionable Beta1.23 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ORIC) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredThe IRS loophole Trump fought to preserve for retirees401(k) balances have reached record highs on a rising stock market and strong job growth. But traditional acco...American Hartford Gold | SponsoredYour first step can stay on paperIncome Blueprint, created by Matt, helps traders find and evaluate options opportunities. In his walkthrough, ...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oric Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oric Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
